Zimmer Biomet Reports 4.8% Increase in Q2 2026 Net Sales to $2.18 Billion

Zimmer Biomet Holdings, Inc. reported a notable increase in financial performance for the second quarter of 2026, with net sales reaching $2,177.0 million, a 4.8% increase from $2,077.3 million in the same period of 2025. For the first half of 2026, the company achieved net sales of $4,263.7 million, up 7.0% from $3,986.4 million year-over-year. The growth was attributed to the acquisition of Paragon 28, favorable foreign currency exchange rates, and increased sales of products such as the ROSA® Robot and bone cement. Net earnings for the second quarter were $198.3 million, compared to $152.8 million in the prior year, while earnings for the first half totaled $436.5 million, up from $334.9 million.

The company experienced significant changes in its operational metrics, with a marked increase in selling, general, and administrative expenses, which rose to $899.3 million in the second quarter from $814.8 million a year earlier. This increase was driven by higher variable selling expenses linked to increased sales, as well as costs associated with the Paragon 28 acquisition. Research and development expenses decreased to $104.8 million from $113.3 million, reflecting a reduction in spending on certain projects and the completion of compliance initiatives related to the European Union Medical Device Regulation.

In terms of geographic performance, U.S. sales grew by 5.6% to $1,239.9 million in the second quarter, while international sales increased by 3.7% to $937.0 million. The Americas segment, which includes the U.S. and parts of Latin America, reported net sales of $1,359.0 million, up from $1,287.0 million in the previous year. The company’s operational restructuring initiatives, which are expected to yield approximately $175 million in annual pre-tax savings by the end of 2027, are also contributing to improved profitability.

Looking ahead, Zimmer Biomet anticipates a year-over-year net sales growth of 3.9% to 4.9% for 2026, driven by market growth, new product introductions, and the ongoing impact of the Paragon 28 acquisition. However, the company also expects challenges from changes in its go-to-market strategy and pricing pressures. The anticipated contributions from the Paragon 28 acquisition are expected to add approximately 1.1% to net sales growth until the one-year anniversary of the acquisition in April 2026. The company remains focused on leveraging its operational efficiencies and managing costs to navigate the evolving market landscape.